BioCentury | Mar 3, 2020
Product Development

Following Phase III readout, Karyopharm seeks approval of Xpovio for second-line MM

Karyopharm gained $11.38 (70%) to $27.72 on Monday, adding about $746 million in market value, after announcing that Xpovio selinexor met the primary endpoint of improving PFS in the confirmatory Phase III BOSTON trial to...
BioCentury | Feb 11, 2020
Product Development

Alzheimer’s prevention replays the same amyloid failures as the treatment setting

...those with mild symptoms from families that carry a genetic mutation in APP, PSEN1 or PSEN2...
...BACE1 - β-site APP cleaving enzyme 1 PSEN1 (PS1) - Presenilin 1 PSEN2 (PS2) - Presenilin 2 Lauren...
BioCentury | Dec 19, 2019

CXCR2 inhibition could overcome androgen receptor antagonist resistance in prostate cancer

DISEASE CATEGORY: Cancer INDICATION: Prostate cancer Inhibiting CXCR2 could treat androgen receptor antagonist-resistant prostate cancer. Knockout of CXCR2, which is found on treatment-resistant, androgen receptor-negative neuroendocrine tumor cells in heterogeneous prostate cancers, restored sensitivity to...
BioCentury | Jun 11, 2019
Distillery Therapeutics

PSEN1 inhibition could treat T cell ALL

DISEASE CATEGORY: Cancer INDICATION: Acute lymphoblastic leukemia (ALL) Cell culture and mouse studies suggest inhibiting PSEN1 could help treat T cell ALL. In two human T cell ALL cell lines, a tool compound PSEN1 inhibitor...
BioCentury | May 31, 2019
Company News

May 31 Company Quick Takes: NMPA accepts two BeiGene applications, approves Hengrui's PD-1 inhibitor; and more

NMPA accepts applications for BeiGene's tislelizumab, Abraxane China's National Medical Products Administration has accepted an sNDA from BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) for tislelizumab to treat previously treated, locally advanced or metastatic urothelial carcinoma. The anti-PD-1...
BioCentury | May 4, 2019
Product Development

How the amyloid hypothesis holds its grip

By now, two things are clear about the amyloid hypothesis of Alzheimer’s disease: one is that the amyloid peptide is somehow involved; the other is that it’s a terrible target. β amyloid has had an...
BioCentury | May 1, 2019
Preclinical News

Ionis' methyl modification could reduce ASO toxicity

Ionis thinks a single methyl modification could reduce hepatoxicity of highly potent antisense oligonucleotides, expanding the opportunities for their development. In a paper published Monday in Nature Biotechnology , Ionis Pharmaceuticals Inc. (NASDAQ:IONS) researchers sought to...
BioCentury | Apr 24, 2019
Company News

AbbVie successor to Humira in psoriasis gains FDA approval

With Humira set to face increasing biosimilar competition internationally this year, AbbVie notched its first U.S. approval for a successor to the blockbuster, Skyrizi risankizumab-rzaa, late Tuesday. FDA approved the IL-23 inhibitor to treat plaque...
BioCentury | Mar 25, 2019
Distillery Therapeutics

Inhibiting EFR3A to treat Alzheimer's disease

DISEASE CATEGORY: Neurology INDICATION: Alzheimer's disease (AD) Mouse studies suggest inhibiting EFR3A could help treat AD. In a transgenic mouse model of AD expressing mutant human amyloid precursor protein (APP) and presenilin 1 (PSEN1; PS1),...
BioCentury | Jan 30, 2019
Distillery Therapeutics

Neurology; cardiovascular

INDICATION: Alzheimer's disease (AD); atherosclerosis Mouse studies suggest inhibiting C5 could help treat AD and atherosclerosis. In a transgenic mouse model of AD expressing mutant human amyloid precursor protein (APP) and presenilin 1 (PSEN1; PS1),...
Items per page:
1 - 10 of 327